Team:Carnegie Mellon/Project/Abstract

From 2013.igem.org

(Difference between revisions)
Line 1: Line 1:
{{:Team:Carnegie_Mellon/Templates/header}}
{{:Team:Carnegie_Mellon/Templates/header}}
<html>
<html>
 +
<br>
<br>
<br>
<br>
<br>
Line 9: Line 10:
<h2>Impact</h2>
<h2>Impact</h2>
<p>
<p>
-
The Center for Disease Control (CDC) released a <a href="http://www.cdc.gov/drugresistance/threat-report-2013/index.html">threat report</a> on September 16th, 2013 on the subject of antibiotic resistant bacteria. Figure 1 shows the timeline for antibiotic discovery and antibiotic resistant strain discovery since 1940. The report identifies 3 types of resistances as "Threat Level: Urgent", 12 types of resistances as "Threat Level: Serious" and 3 types of resistances as "Threat Level: Concerning". The CDC reports 4 major steps to tackle the problem including:
+
On September 16, 2013 the CDC released to the public <a href="http://www.cdc.gov/drugresistance/threat-report-2013/index.html">“Antibiotic Resistance Threats in the United States, 2013”</a>. This document is intended to raise public awareness of the problems associated with overuse and misuse of antibiotics and to outline the threats to society caused by these organisms. The organisms have been categorized by hazard level as urgent, serious and concerning. Over 2 million illnesses and 23,000 deaths per year are a direct result of antibiotic resistance. The CDC reports 4 major steps to tackle the problem including:
<ol>
<ol>
<li>Preventing Infections, Preventing the Spread of Resistance</li>
<li>Preventing Infections, Preventing the Spread of Resistance</li>
Line 17: Line 18:
</ol>
</ol>
<br>
<br>
-
Unfortunately, antibiotic development have been on the decline for quite some time. There is a demand for new technologies to help effectively treat infections. Figure 2 shows the drug pipeline since 1980.
+
<h2>Summary</h2>
 +
<p>
 +
There is a great need for new antimicrobial strategies. Phage therapy represents a completely different solution. Incorporating KillerRed phototoxicity provides another level of controlled killing. Phages are biological entities, which, theoretically, can be engineered to evolve at rates comparable of the natural evolution of bacteria if they happen to develop resistances to infection. Many phages are temperate, meaning that they can enter the lysogenic phase, which is undesirable for a killing phage. The addition of KillerRed to the system offers a second method of killing in the lysogenic phage. Thus, our system explores the possibility that temperate phages can also be used for phage therapy and bacteria killing applications. Our project establishes a first step in the production of phage therapies that
 +
</p>
 +
 
 +
<h2>Background</h2>
 +
<br>
 +
<b>Discovery of Antibiotics</b>
 +
<br><p>
 +
Arsphenamine is an arsenic compound  that was discovered in 1909, to have antisyphilitic properties by Sahachiro Hata and Paul Ehrlich. In 1929, Sir Alexander Fleming published the results of his study of a substance that he named penicillin. This compound was released by Penicillium fungi and killed bacteria. These antibiotics function by inhibiting an enzyme involved in crosslinking of the peptidoglycan cell wall of gram-positive bacteria. Resistance to the beta lactam antibiotics is derived from beta-lactamase, an enzyme that cleaves the drug and inactivates it. The gene for this enzyme is commonly used as a selectable marker in recombinant DNA laboratories to confer resistance to ampicillin. Today there are antibiotics of the cephalosporin family that are derived from the compound  isolated in 1945 by Giuseppe Brotzu, from the fungus Cephalosporium acremonium.</p>
 +
 
 +
 
<br><table border="1">
<br><table border="1">
<tr><td>
<tr><td>

Revision as of 16:32, 26 September 2013

Killer Red





Abstract

Due to the widespread misuse and overuse of antibiotics, drug resistant bacteria now pose significant risks to health, agriculture and the environment. An alternative to conventional antibiotics is phage therapy. However, many temperate phage also form prophage. Our approach to antibiotic resistance is to engineer a temperate phage, Lambda, with light-activated production of superoxide. The fluorescent protein KillerRed was cloned into a plasmid vector and lambda gt11 with the IPTG inducible lac promoter. Lysogens were isolated and these strains were characterized and compared to E. coli with KillerRed from high-copy plasmids. Light activation of KillerRed resulted in decreased cell numbers. In addition, we modeled our system at multiple scales, including populations of phage and bacteria, KillerRed gene expression, ROS production, and effects of light. Having two methods of killing, lysis and superoxide, decreases the probability of developing resistance and our system overcomes the prior limitations of using wild-type temperate phages.


Impact

On September 16, 2013 the CDC released to the public “Antibiotic Resistance Threats in the United States, 2013”. This document is intended to raise public awareness of the problems associated with overuse and misuse of antibiotics and to outline the threats to society caused by these organisms. The organisms have been categorized by hazard level as urgent, serious and concerning. Over 2 million illnesses and 23,000 deaths per year are a direct result of antibiotic resistance. The CDC reports 4 major steps to tackle the problem including:

  1. Preventing Infections, Preventing the Spread of Resistance
  2. Tracking
  3. Improving Antibiotic Prescribing/Stewardship
  4. Developing New Drugs and Diagnostic Tests

Summary

There is a great need for new antimicrobial strategies. Phage therapy represents a completely different solution. Incorporating KillerRed phototoxicity provides another level of controlled killing. Phages are biological entities, which, theoretically, can be engineered to evolve at rates comparable of the natural evolution of bacteria if they happen to develop resistances to infection. Many phages are temperate, meaning that they can enter the lysogenic phase, which is undesirable for a killing phage. The addition of KillerRed to the system offers a second method of killing in the lysogenic phage. Thus, our system explores the possibility that temperate phages can also be used for phage therapy and bacteria killing applications. Our project establishes a first step in the production of phage therapies that

Background


Discovery of Antibiotics

Arsphenamine is an arsenic compound that was discovered in 1909, to have antisyphilitic properties by Sahachiro Hata and Paul Ehrlich. In 1929, Sir Alexander Fleming published the results of his study of a substance that he named penicillin. This compound was released by Penicillium fungi and killed bacteria. These antibiotics function by inhibiting an enzyme involved in crosslinking of the peptidoglycan cell wall of gram-positive bacteria. Resistance to the beta lactam antibiotics is derived from beta-lactamase, an enzyme that cleaves the drug and inactivates it. The gene for this enzyme is commonly used as a selectable marker in recombinant DNA laboratories to confer resistance to ampicillin. Today there are antibiotics of the cephalosporin family that are derived from the compound isolated in 1945 by Giuseppe Brotzu, from the fungus Cephalosporium acremonium.



Figure 1:Antibiotic resistance timeline since 1940

Figure 2: Antibiotic development pipeline since 1980



References

Antibiotic resistance threats in the United States, 2013. The Center for Disease Control. 9/16/2013.